E-cigarette vapor contains more carcinogenic formaldehyde than regular cigarettes
the ONA take:
E-cigarette vapor may contain cancer-causing formaldehyde at a level 15 times higher than normal cigarettes, according to a new study published in the New England Journal of Medicine.
“We’ve found that there is a hidden form of formaldehyde in e-cigarette vapor that has not typically been measured,” said James Pankow, PhD, co-author of the study along with fellow researchers at Portland State University in Oregon. “People shouldn’t assume these e-cigarettes are completely safe.”
While once believed to be a less harmful alternative to the formaldehyde and toxic chemicals found in the smoke of normal cigarettes, newer e-cigarettes operate at high temperatures that dramatically boost the creation of formaldehyde-containing compounds.
The researchers found that, at high voltage, formaldehyde-releasing agents in e-cigarettes increased a person’s lifetime risk of cancer by five-to-15 times greater than the risk of long-term smoking with regular cigarettes. However, the compounds were not found when they were operated at a lower voltage.
The American Vaping Association, an advocacy group for e-cigarette makers, criticized the study, stating that users wouldn’t normally operate devices at such a high voltage.
E-cigarettes remain unregulated, and representatives from the American Cancer Society stated that the findings from the study stress the importance of FDA oversight.
E-cigarette vapor may contain cancer-causing formaldehyde at a level 15 times higher than normal cigarettes.
Sign Up for Free e-newsletters
- Avoiding the ED: Planned Strategies for Unplanned Urgent Cancer Care
- NP-Led Clinics Improved Phase 1 Oncology Study Operations, Outcomes
- Art as Palliative Care: Bedside Intervention Improves Pain, Anxiety, Mood in Hospitalized Cancer Patients
- Unprotected Sex After Chemotherapy
- Mindfulness Training May Improve End-of-Life Conversations in Advanced Cancer
- Study Suggests Greater Focus on the Needs of Family Caregivers of Patients With Cancer
- First Antibody-Based Treatment Regimen Approved for First-Line Treatment of Multiple Myeloma
- Increased Diabetes Risk Associated With Cancer Development
- Childhood Neuroblastoma Survivors at Risk for Psych Impairment
- Drug Classification of Trastuzumab
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|